Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK ( TheStreet) -- CHANGE IN RATINGS
Auxilium Pharmaceuticals (AUXL) rated new Buy at UBS. $30 price target. The company's two lead products are underappreciated by the market.
CH Robinson (CHRW) upgraded at Deutsche from Hold to Buy, Deutsche Bank said. $86 price target. Company is leveraged to tighter trucking capacity.Cisco Systems (CSCO - Get Report) downgraded at Auriga from Buy to Hold, Auriga USA said. $19 price target. Company is likely to face increased competition in the coming quarters. CVR Energy (CVI) initiated at Credit Suisse with an Outperform rating and $30 price target. Strong earnings power not priced in, Credit Suisse said. Dr. Pepper Snapple (DPS) downgraded at Deutsche from Buy to Hold, Deutsche Bank said. Valuation call, as the company lacks near-term catalysts. $40 price target. FirstEnergy (FE) upgraded at Jefferies from Underperform to Hold. $38 price target. Expect the company to maintain its investment grade rating. Finish Line (FINL) upgraded at Citigroup to Buy from Hold. Margin expansion on strong footwear cycle. Price target increased to $25 from $22. Fifth Third (FITB - Get Report) upgraded at Baird from Neutral to Outperform, Robert Baird said. $17 price target. Large-cap banks appear oversold and the stock is trading at just 9x expected 2012 earnings. Google (GOOG) downgraded at Credit Suisse to Hold from Buy as it is now a "show-me story," Credit Suisse said. Price target lowered to $650 from $750. Hasbro (HAS - Get Report) upgraded at Morgan Joseph from Hold to Buy, Morgan Joseph said. $54 price target. Company has handled its inventory issues and has several potential near-term catalysts. Hasbro (HAS - Get Report) estimates, target lowered at Goldman. Shares of HAS now seen reaching $58, according to Goldman Sachs. Estimates also cut, as the company is realizing higher costs from its TV venture. Buy rating. Harley-Davidson (HOG - Get Report) upgraded at Goldman from Sell to Neutral, Goldman Sachs said. $44 price target. Domestic bike demand is stabilizing. Impax Labs (IPXL) rated new Neutral at UBS. $30 price target. Company is facing increased generic competition. Rosetta Resources (ROSE - Get Report) upgraded at Canaccord to Buy, Canaccord Genuity said. Valuation call, based on a $53 price target.